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Abstract Both Epstein^Barr virus (EBV) and p53 have independently been associated with idiopathic pulmonary
¢brosis (IPF).This study explores further whether a relationship potentially exists between EBVand p53 in IPF, thereby
providingapossiblemechanismfor therole of EBVinthediseaseprogressionof IPF.Lung tissue fromopenlungbiopsiesof
14 IPF patients was comparedwith a control group of19 patients. EBV status was determined using both immunohisto-
chemistry and PCR, while p53 expressionwas assessedwith immunohistochemistry. Seven of14 IPF patients expressed
p53 comparedto one of19 control subjects (P= 0?011).Eight IPF patients andno controlswerepositive for EBV (P50?01).
Four IPF patients demonstratedboth EBVandp53 expression comparedwithno controls, (P= 0?05).This study suggests
that a relationship between EBVandp53 mayexist in patientswith IPF.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1152, available online at http://www.idealibrary.comon
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Idiopathic pulmonary ¢brosis (IPF) occurs following an
environmental lung injury in susceptible individuals (1).
The primary injury to the respiratory epithelium results
in healing and regeneration (1).With the loss of cell integ-
rity, certain cell cycle control proteins (proto-onco-
genes) are expressed to prevent the progression of
abnormal and defective cells during repair.These proto-
oncogenes result in either a cessation of cellular growth
to allow the cell to recover or induce programmed cell
death if repair is not possible (apoptosis).One such pro-
tein critical to cell cycle regulation is the p53 tumour
suppressor protein. During the repair process, the
expression of mitogenic factors are suppressed by
p53 activity, whose peak action occurs when
re-epithelialization is complete (2). The interference of
the normal p53 function may result in unregulated
growth factor expression and possibly abnormal
epithelial cell repair. A normal intact epithelium itself is
important in the control of the repair mechanism (3,4).
Kuwano et al. have shown that there is over-expres-
sion of p53 with evidence of DNA damage in the epithe-
lial layers of lung tissue obtained from patients with IPFReceived 22December 2000 and accepted in revised form 23May 2001
Correspondence shouldbe addressed to: She S.Lok,Departmentof
RespiratoryMedicine,Queen Elizabeth IIHospital,Howlands,Welwyn
GardenCity, AL 7H 4HQ,UK.Fax:441707 5058; E-mail: sslok@aol.com(5). An association between Epstein^Barr virus (EBV)
and IPF has also been established implying a potential
involvement of viruses in the pathogenesis of IPF (6,7),
although Wangoo et al. suggested no such relationship
(8). The possible mechanisms by which EBVmay contri-
bute to the pathogenesis of IPF includes: (a) in£uencing
cytokine balance in lung injury and repair, or (b) in£uen-
cing proto-oncogenes proteins in the cell cycle involved
in cellular growth and control.
Zhanget al. has previously shown that EBV canmodify
p53 protein expression (9), thereforewe postulated that
EBV persistence in pulmonary epithelial cellsmaymodify
epithelial cell repair and apoptosis in IPF patients.
The object of this study was to identify whether both
p53 expression (wild and mutant) and EBV persistence
existed in the epithelial cells of lung tissue from IPF
patients compared to controls.
METHODS
Fourteen archival lung biopsies from IPF patients were
randomly selected for the study [12 fromopen lung biop-
sies (OLB), two from lung removed at transplantation].
The lung tissue were ¢xed in bu¡ered formalin and
stainedwith haemotoxylin and eosin (H&E).These biop-
sies were reviewed by a pulmonary histopathologist
(P.S.H.) to con¢rm patterns consistent with the usual
interstitial pneumonia (UIP) form of IPF, and to exclude
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interstitial pneumonia (NSIP) and desquamative
interstitial pneumonia (DIP). Histological features on
biopsy examined for were: (1) a variegated picture of
¢brosis, in£ammation and normal lung; (2) exclusion
of evidence to suggest another pathology (e.g. asbestos
bodies, granuloma, etc.); (3) a tendency for pleural and
sub-pleural-based distribution of ¢brosis.
OLB were performed either by a VATS procedure
or by open thoracotomy with the site of operation
directed by high-resolution computer tomography
(HRCT). CT criteria for diagnosing IPF (UIP) were: (1)
symmetrical bilateral interstitial in¢ltrates; (2) pulmon-
ary in¢ltrate a¡ecting the bases of the lung and
distributed subpleurally; (3) presence of honeycombing
of the lung with sub-pleural distribution; (4) predomi-
nance of ¢brosis and minimal areas of ground glass
shadowing (grade III) (10).
Nineteen patients who underwent pneumonectomies
or OLB for pulmonary pathology were used as controls
(11OLB, three from lung removed at transplantation and
¢ve from pneumonectomy or lobectomy performed for
lung cancer).
In those control lung specimens where the
primary diagnosis was cancer, lung tissue away from the
malignant lesion was used for the study.The lung tissues
were examined for the presence of p53 (both mutant
and wild-type) using immunohistochemistry, while
EBV was detected by both PCR and immunohistochem-
istry. The lung specimens were coded and assessed
blind for thepresence of p53 and EBV by the histopathol-
ogist (P.S.H.).
Immunohistochemistry for p53
Using para⁄n-preserved lung tissue 5mm sections were
cut. These were dried overnight in an incubator at 378C
and then at 568C for 30min.The sections were dewaxed
using xylene and dehydrated by bringing to absolute
alcohol. Staining of the p53 employed a streptavidin
peroxidase technique (duet, DAKO) according to the
manufacturers’ instructions using DAB (3,3’-diamino-
benzidine tetrahydrochloride) as substrate, which visua-
lizes the peroxidase tracer. Two primary p53 antibodies
were used: NCL-p53-1801 (Novo Castra Laboratories
Ltd,Newcastle,U.K.), an indexmouse antibody in1: 40 di-
lution, which recognizes both wild and mutant p53 and
MCA909 (Serotec Ltd, Oxford, U.K.), an index mouse
antibody in 1: 40 dilution which recognizes mutant p53
only. Samples staining positive for the NCL-p53-1801 and
negative for MCA909 were considered positive for wild
p53.Negative controls were sections deprived of the pri-
mary antibody and the positive controls were sections
known to contain p53.Only nuclear staining of the cell by
the antibody was considered positive for p53.Immunohistochemistry for EBV
This was performed as described in a previous study (7).
In each case, 5mm sections were analysed for the pre-
sence of the EBV productive cycle by using monoclonal
antibodies speci¢c for the EBV structural antigen gp350/
220 and VCA. Sections were ¢rst incubated at 48C over-
night in a solution of 20% (w/v) bovine serum albumin to
block non-speci¢c binding of antibodies. Staining for EBV
lytic cycle antigens and cellular antigen was performed
using a Vectastain Elite ABC kit (Vector Laboratories,
Burlingame,CA,U.S.A.) according to the manufacturer’s
protocol. Primary antisera were mouse monoclonal re-
agents including: anti-EBVmembrane antigen gp340/220;
anti-EBV VCA (MAB 817; Chemicon International
Temecula, CA, U.S.A.); anti-epithelial membrane antigen
EMA (M613; Dakoplatts, Copenhagen, Denmark) anti-
CD20, a pan B cell antibody (M755; Dakoplatts). Puri¢ed
anti-gp 340/220wasused at a concentration of10mgml71
and anti-VCAwas used at a 1:400 dilution. To assess the
speci¢cities of the reagents used, reaction against an
EBV-positiveB-cell lineB95-8 andEBV-negativeB cell line
BL41wereused as control. Antigens expressedduring the
latent phase of EBV life cycle (LMP) were not studied.
PCR for EBV
Thiswasperformedaspreviouslydescribed (7).DNAwas
extracted from 5mm sections that were serially
adjacent to those analysedby IHCusingQiamp tissuekits
(Qiagen). Control DNA was extracted from the B lym-
phocyte cell lines AM (11) (EBV-positive) and BL41 (12)
(EBV-negative). Pilot studies were performed to analyse
the abilityof extractedDNAtobe ampli¢edby PCRusing
primers speci¢c for the human p53 gene (13). This indi-
cated that ampli¢able DNAwas best obtained if protei-
nase K digestion of the samplewas extended from12h to
5 days. Ampli¢ableDNA (100ng)was subjected to nested
PCR analysis using oligonucleotide primers speci¢c for
EBV and recombinant Taq DNA polymerase (Gibco/
BRL, Parsley U.K.). The ¢rst round of PCR used the pri-
mers 5’ -GGTCCCGTAGTGACAACTATGCTG and 5’ -
GAGTGCACCACAGCCAACTCCATG at an annealing
temperature of 608C for 40 cycles as described by Lees
et al. (14). The second (nested) round of PCR used the
primers 5’ -GGCTTTGGGTTCCATTGTGTGC and
5’ -TGTACAGAACCAAAGAGGTGGC at an annealing
temperature of 608C for 25 cycles. PCR products were
electrophoresed through 2% agarose gels and DNA
visualizedby ethidiumbromide staining.Molecularweight
determinations were made using the 1kB ladder (Gibco/
BRL). Positive signal for EBV yielded a 284bp product.
Limiting dilution of a known amount of cloned target
DNA showed that the PCRwas sensitive to one copy of
EBV DNA. Sections were randomized, analysed by PCR
blind and the results decoded subsequently.









1  7    
2 7 7 7   
3 7 7 7   
4 7 7 7 7  7
5 7 7 7 7 7 7
6  7  7 7 7
7  7  7  7
8   7 7 7 7
9 7 7 7   
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The demographic data was compared using a non-para-
metric statistical analysis (Mann^Whitney U-test). EBV
and p53 staining in the IPF and control patients were
compared using the Chi-squared test withYates’ correc-
tion. To determine if there was a statistical relationship
between EBVandp53 positivity cross-tabswas usedwith
kappa correction. The SPSS package was used for the
statistical calculations.
RESULTS
The demographics of the patients studied were closely
matched for age and sex (Table1).The primary diagnoses
of the control patients are shown inTable 3.
Staining of lung tissue for p53 and EBVare summarized
in Tables 2, 3 and 4. Lung tissue from IPF patients had
more frequent staining for p53 (seven of 14 IPF patients
compared to one of19 controls,P=0?011). Six IPFpatientsTABLE 1. Demographics of patients inthe study
IPF Controls P7value
Patients 14 19
Sex (females/%) 4 (28) 10 (55) 0?38
Age 59 53 0?11
TABLE 3. p53 and EBV stainingof controls
Patients W&Mp53 Mp53 Wp53 EBV
15 7 7 7 7
16 7 7 7 7
17 7 7 7 7
18 7 7 7 7
19 7 7 7 7
20 7 7 7 7
21 7 7 7 7
22 7 7 7 7
23 7 7 7 7
24 7 7 7 7
25  7  7
26 7 7 7 7
27 7 7 7 7
28 7 7 7 7
29 7 7 7 
30 7 7 7 7
31 7 7 7 7
32 7 7 7 7
33 7 7 7 7
Lung ca = lung carcinoma (non-small cell); normal = no abnor
alveolitis;CF = cystic ¢brosis.were positive for wild p53 and only one of the control
patients,P=0?029.One IPF patients was positive formu-
tant p53 compared with no controls, P=0?88). Ten IPF
patients stained positive for EBV compared with four10  7    
11 7 7 7   
12  7    
13 7 7 7 7 7 7
14  7    
W&Mp53 = staining forwild andmutantp53;M p53 =
mutantp53 present;W p53 =wildp53 present;EBVPCR
= staining for EBVDNA;EBVIHC= staining for EBVVCA
andgp 340/220.




















malities found; sarcoid = sarcoidosis; EAA = extrinsic allergic






p53 (W&M)-positive 7 1 0?011
Wildp53-positive 6 1 0?029
Mutantp53-positive 1 0 0?88
EBV-positive (PCR and IHC) 8 0 50?01
EBV-andp53-positive 4 0 0?05
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eight IPF patients who were positive by immunohisto-
chemistry and PCR compared to no controls (P50?01).
Only IPF patients were positive for both EBV and p53
(four of 14) compared to no controls (zero of 19),
P=0?05. There was no statistical correlation between
EBVand p53 staining.
DISCUSSION
This study suggests that a potential relationship exist be-
tween p53 and EBV in IPF patients, providing a possible
mechanism by which EBV may contribute to epithelial
cell injury.Bothwildp53 staining and EBVpositivity were
localized to the epithelial cell layer of IPF patients. How-
ever a statistical correlation between p53 staining and
EBV was not established.
These data show that wild p53 expression occurs
more frequently than the mutant p53 in IPF patients,
which is consistent with the ¢ndings of Kuwano et al. In
their study, Kuwano et al. established a relationship be-
tween p53 and IPF (5). They studied 14 IPF patients and
17 controls (normal lungs and pulmonary emphysema)
and found that p53 was detected in the hyperplastic
epithelial layer of IPF lung tissue but not controls. This
correlatedwith evidence of cell death in this same region
of IPF patients, as detectedby theTUNEL (TdT-mediated
dUTP-biotin nick-end labelling) method. They postu-
lated that the up-regulation of p53 in the face of chronic
DNA damage may increase the potential in mutation of
p53, leading to increased tumorigenesis in IPF. However,
they did not di¡erentiate between wild and mutant p53,
as this study has done.Kuwano inferred that p53 staining
was wild-type because of the presence of p21 (a down-
streamprotein important in the function of p53 and only
produced by wild p53).
The presence of p53 in ¢brotic lung may therefore
re£ect: (1) an excess of injured cells or (2) a normal re-
sponse to control the growth of damaged cells! The up-
regulation of p53 seen in the data may re£ect a response
to injury.Cells with damaged DNA are halted at the G1
checkpoint and prevented from entering the S phase ofcell replication by the p53 checkpoint protein (15). Cell
division is also halted at the G2 checkpoint and pre-
vented from entering interphase, hence preventing pro-
liferation of abnormal cells. Cells either undergo DNA
repair or programmed death (apoptosis) (15).
EBV caninterferewith the function ofp53.This activity
can be achieved by the action of BZLF-1 [also called
ZEBRA (BamH1 Z EBV replication activator), Zta or
EB1] an AP-1 transcriptional trans-activator protein
important in EBV replication, as shown by Zhang et al.
(9).The role of the BZLF-1protein is to facilitate the pro-
pagation of EBV in the host by interfering with the regu-
lation of the cell cycle. Such an action has led to the
proposed tumourigenicity e¡ect of EBV (14), although in
EBV-related malignancies such as Burkitt’s lymphoma
there is no relationship between EBV and p53 (12). In
addition, Szekelyetal. have suggested that the EBV leader
protein expressed during latency, EBNA-5 (EBV nuclear
antigen 5) can also interact with p53 (16). In this study
they found that the EBNA-5 protein binds with p53,
resulting in an immunoprecipitate. However, it is not
knownwhether p53 function is a¡ectedby this particular
interaction. Gan et al. has shown that ZEBRA does not
a¡ect mutant p53 and functions only in the presence of
wild p53 (17).This study supports the role of a potential
interaction between p53 and EBV in IPF patients.There-
fore it is possible that an interaction between EBV pro-
teins and p53 may play a role in the disease progression.
We have not identi¢ed p53 staining in the ¢broblasts.
The abnormal degree of ¢brosis implies overactivity of
collagen production from ¢broblasts, and in patients
with Li-Fraumeni syndrome, examination of ¢broblasts
show abnormalp53withresultantprolongation and even
immortalization of ¢broblasts (18). However, the role of
p53 on the actions of in£ammatory cells and ¢broblasts
can be indirect through its e¡ects on the epithelium.We
believe epithelial cells are critically important e¡ector
cells in IPF (3,4,19).
Epithelial cells appear to have a role in normal ¢bro-
blast function, as a result of cell to cell interaction. An
intact, normally functioning epitheliummaybe responsi-
ble for controlling the release and actions of cytokines
present during epithelial repair (19). Our data showed
that p53 and EBV were both found in the epithelial layer.
The consequence is a potential viral mediated inhibition
of p53 action (through the expression of ZEBRA) on the
repair of cells with damaged DNA (9). The failure of
repair to the epithelium could therefore a¡ect the cyto-
kine balance.The potential role of EBVon the actions of
p53 is comparable to the e¡ects of humanpapillomavirus
on p53 (20). Papilloma virus produces proteins that bind
with and degrades the p53 protein.
Ideally the use of normal lung tissue as controls would
have excluded the role of an underlying lung disease,
in£uencing the results.This ethically would not be possi-
ble. In the controls, lung tissue obtainedmainly from pa-
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sociation of lung cancer with p53 has been shown (21).
However, lung tissue away from the primary lesion was
used. In the study p53 positivity was not elevated in the
lung cancer controls. In addition the relationship identi-
¢ed in this study was with wild p53 rather than mutant
p53. Kunitake et al. showed that p53 was not elevated in
lung tissue from patients with sarcoidosis (22) although
theyreported a relationship ofp53with collagenvascular
disease.The use of non-normal lung tissue therefore did
not appear to a¡ect the results.
EBV, in the course of replication, can also interfere
with cytokine balance. Klein et al. in a study of EBV in-
fected cell lines, found that there was increased expres-
sion of IL-8, IL-10,TNFa and TNFb by these infected cells
(23). The cytokine imbalance induced by EBV, together
with the impairment of cytokine regulation through the
e¡ect on the epithelial layer, may initiate the events lead-
ing to the development of ¢brosis.
An initial lung insult may result in an over-expression
of p53. Mishra et al. reported that an acute lung injury
from bleomycin may be a p53-mediated response (24).
A lung injury in the presence of active EBV replication
may lead to disruption of normal p53 function and cell
regulation. This study suggests an association between
p53 and EBV in the epithelial cells of lung tissue of
IPF pateints, supporting a hypothesis of a viral-mediated
dysregulation of epithelial cell repair.However, furtherin
vitro studies would be required to determine the
precise relationship.
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